Definium Therapeutics, Inc. (DFTX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 4.59B USD. 52-week range 10.46 to 49.70 USD. Data as of 2026-10-09.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind ...